FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

On June 22, 2017, the Food and Drug Administration expanded indications for dabrafenib and trametinib to include treatment of patients with metastatic non‐small cell lung cancer (NSCLC) harboring BRAF V600E mutations. Approval was based on results from an international, multicenter, multicohort, non...

Descripción completa

Detalles Bibliográficos
Autores principales: Odogwu, Lauretta, Mathieu, Luckson, Blumenthal, Gideon, Larkins, Erin, Goldberg, Kirsten B., Griffin, Norma, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Jiang, Xiaoping, Rodriguez, Lisa, McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067947/
https://www.ncbi.nlm.nih.gov/pubmed/29438093
http://dx.doi.org/10.1634/theoncologist.2017-0642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067947/
https://www.ncbi.nlm.nih.gov/pubmed/29438093
http://dx.doi.org/10.1634/theoncologist.2017-0642

Ejemplares similares